{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:36:35Z","timestamp":1789580195505,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the clinical efficacy and safety of topical antimicrobial peptide PL\u20105 (Peceleganan) spray combined with standard debridement in the treatment of mildly to moderately infected diabetic foot ulcers (DFUs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This multicenter, randomized, double\u2010blind, placebo\u2010controlled trial was conducted in four tertiary hospitals. Eligible patients were randomized to PL\u20105 spray or placebo, both receiving standardized debridement. The primary endpoint was clinical response rate at 1\u2009day after end of treatment (EOT1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline characteristics were balanced between groups. The clinical response rate at EOT1 was significantly higher in the PL\u20105 group than in the placebo group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The clearance rate of drug\u2010resistant bacteria at EOT1 was 71.43% in the PL\u20105 group versus 50% in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). No significant differences were observed in overall microbiological eradication rates at EOT1 (57.89% vs. 33.33%) or EOT7 (64.71% vs. 40.00%) (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Adverse event rates were 24.24% in the PL\u20105 group and 33.33% in the placebo group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05), with no serious drug\u2010related adverse events. PL\u20105 showed a significant improvement in clinical effective rate, but overall microbiological eradication was not significantly different between groups. However, in the subset of patients with drug\u2010resistant bacteria, PL\u20105 demonstrated a significantly higher clearance rate, suggesting potential for treatment of resistant infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Topical PL\u20105 spray improves clinical outcomes in mild\u2010to\u2010moderate infected diabetic foot ulcers and achieves superior pathogen clearance among drug\u2010resistant infection subgroups. It represents a promising low\u2010resistance topical option for managing mild to moderate DFU infections.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial Registration:<\/jats:bold>\n                      Chinese Clinical Trial Registry Identifier: ChiCTR2300068632\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1753-0407.70255","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:34:19Z","timestamp":1785206059000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Topical Application of Antimicrobial Peptide\n                    <scp>PL<\/scp>\n                    \u20105 (Peceleganan) Spray on Mild to Moderate Infection of Diabetic Foot Ulcers: A Multicenter, Randomized, Double\u2010Blinded, Placebo\u2010Controlled Clinical Trial"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6833-5080","authenticated-orcid":false,"given":"Li","family":"Qian","sequence":"first","affiliation":[{"name":"Department of Endocrinology Sir Run Run Hospital, Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology JunXie Hospital  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rourou","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Sir Run Run Hospital, Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Sir Run Run Hospital, Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics Sir Run Run Hospital, Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology The First People's Hospital of Lianyungang  Lianyungang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Huai'an Second People's Hospital  Huai'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfang","family":"Che","sequence":"additional","affiliation":[{"name":"Department of Endocrinology JunXie Hospital  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology JunXie Hospital  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Jiangsu Protelight Pharmaceutical Company  Jiangyin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6012-5305","authenticated-orcid":false,"given":"Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Sir Run Run Hospital, Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"8","key":"e_1_2_13_2_1","first-page":"1036","article-title":"Diabetes\u2010Related Lower\u2010Extremity Complications Are a Leading Cause of the Global Burden of Disability","volume":"35","author":"Lazzarini P. A.","year":"2018","journal-title":"Diabetic Medicine"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jfas.2014.06.011"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13537"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1614"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh531"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67694-5"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm130"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767020-00003"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.2005.3301"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/415389a"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe020106"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2219-3"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005508"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3687"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/511036"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13507"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.03.049"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2021.0144"},{"issue":"6","key":"e_1_2_13_20_1","first-page":"CD011038","article-title":"Topical Antimicrobial Agents for Treating Foot Ulcers in People With Diabetes","volume":"6","author":"Dumville J. C.","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00925-06"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2006.00349.x"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050312118773950"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.7547\/1020223"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-481X.2007.00363.x"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.7547\/1010484"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1534734610361945"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1086\/593185"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2706"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3730"}],"container-title":["Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1753-0407.70255","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1753-0407.70255","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1753-0407.70255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:14:47Z","timestamp":1785320087000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1753-0407.70255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/1753-0407.70255"],"URL":"https:\/\/doi.org\/10.1111\/1753-0407.70255","archive":["Portico"],"relation":{},"ISSN":["1753-0393","1753-0407"],"issn-type":[{"value":"1753-0393","type":"print"},{"value":"1753-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70255"}}